Pfizer Signs a Worldwide License Agreement with Theravance BioPharma for its Pan-JAK Inhibitor Program

 Pfizer Signs a Worldwide License Agreement with Theravance BioPharma for its Pan-JAK Inhibitor Program

Pfizer Signs a Worldwide License Agreement with Theravance BioPharma for its Pan-JAK Inhibitor Program

Shots:

  • Theravance to receive $10M up front, up to $240M development & commercial milestones with royalties on global sales of any product developed from the program. Pfizer to get a global license for Theravance’s skin-targeted, LA, pan-Janus kinase (JAK) inhibitors  
  • Pfizer will validate Theravance’s expertise in the discovery & development of organ-selective JAK inhibitors while the program will complement Pfizer’s portfolio of pre/ clinical-stage molecules targeting unmet medical needs
  • JAK inhibitors act by targeting the JAK enzyme, thus interfering with the JAK/STAT signaling pathway which resulted in modulating the activity of a wide range of pro-inflammatory cytokines. The compounds in the program are designed to possess skin-selective activity with minimal systemic exposure

Click here ­to­ read full press release/ article | Ref: Theravance | Image: Office Snapshot

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post